Hematology (all articles)
Guideline | Anemia management in surgical patients.
23 Sep, 2022 | 13:11h | UTC
Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.
23 Sep, 2022 | 13:07h | UTC
Commentary on Twitter
Chimeric antigen receptor T cells have revolutionised the treatment of hematological malignancies.
What practical aspects of a patient’s journey through this treatment should clinicians know about and what are current best practices to manage toxicities?https://t.co/idlA2Lv9uR
— The BMJ (@bmj_latest) September 4, 2022
A quality improvement study showed that a clinic–based aspirin deimplementation intervention can reduce inappropriate aspirin prescribing and bleeding in patients receiving warfarin for anticoagulation.
22 Sep, 2022 | 13:14h | UTCNews Release: Stopping aspirin when on a blood thinner lowers risk of bleeding, study finds – Michigan Medicine
Commentary on Twitter
An anticoagulation clinic–based #aspirin deimplementation intervention was associated with improved guideline-concordant aspirin use and fewer bleeding complications. https://t.co/kxKFZOdhae #Research
— JAMA Network Open (@JAMANetworkOpen) September 19, 2022
Case report and brief review | Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus.
20 Sep, 2022 | 13:17h | UTC
AHA Scientific Statement | Management of patients at risk for and with left ventricular thrombus.
16 Sep, 2022 | 13:00h | UTC
Review | Obesity and contraceptive use: impact on cardiovascular risk.
16 Sep, 2022 | 12:53h | UTCObesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure
News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology
NCCN Guideline | Myeloproliferative neoplasms.
15 Sep, 2022 | 13:05h | UTC
M-A | Blood type linked to the risk of stroke before age 60.
13 Sep, 2022 | 13:17h | UTCContribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)
News Releases:
Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology
Blood Type Linked To Stroke Risk Before 60 – University of Maryland
Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.
13 Sep, 2022 | 12:59h | UTCCommentaries:
CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)
CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)
Commentary on Twitter
NEW research—tisagenlecleucel has antitumour activity and acceptable safety in young children and infants (aged younger than 3 years at screening) with B-cell ALL: results of an international, retrospective study #leusm #pedonc #tcellrx https://t.co/kdh3dW5PRU pic.twitter.com/FgQZKQWtXV
— The Lancet Haematology (@TheLancetHaem) September 8, 2022
RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.
11 Sep, 2022 | 22:24h | UTC
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
Systematic Review | Hypoxia‐inducible factor stabilizers for the anemia of chronic kidney disease.
8 Sep, 2022 | 14:35h | UTCHypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library
RCT | Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time.
8 Sep, 2022 | 14:34h | UTCLenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link to abstract – $ for full-text)
48-week follow-up of a RCT | Pegcetacoplan vs. Eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
8 Sep, 2022 | 14:29h | UTCPegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine
Commentary on Twitter (thread – click for more)
NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X
— The Lancet Haematology (@TheLancetHaem) September 1, 2022
Opinion | Tranexamic acid for safer surgery: the time is now.
7 Sep, 2022 | 12:37h | UTCTranexamic acid for safer surgery: the time is now – British Journal of Surgery
Related:
Update on applications and limitations of perioperative tranexamic acid.
Review | Diagnosis and treatment of myelodysplastic syndromes.
7 Sep, 2022 | 12:33h | UTCDiagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Myelodysplastic Syndromes – JAMA
Cohort Study | Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria.
7 Sep, 2022 | 12:29h | UTCClinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Super excited to share our multicenter study on clonal evolution in 1008 patients with AA/PNH followed for a median f-up of 9 yrs now out in @JCO_ASCO https://t.co/j9U2ZjYX0o
— Carmelo Gurnari (@CarmeloGurnari) September 2, 2022
Brief Review | Thromboprophylaxis in critical care.
6 Sep, 2022 | 14:41h | UTCThromboprophylaxis in critical care – Intensive Care Medicine
Review | The use of whole blood transfusion in trauma.
6 Sep, 2022 | 14:15h | UTCThe Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports
Systematic Review | Hydroxyurea for sickle cell disease.
5 Sep, 2022 | 14:14h | UTCHydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library
Summary: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library
Systematic Review | The effect of heparin and its preparations on disseminated intravascular coagulation mortality and hospitalization.
1 Sep, 2022 | 11:34h | UTC
Long-term results of a RCT | Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in chronic lymphocytic leukemia.
31 Aug, 2022 | 11:32h | UTCCommentary: Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status – Cancer Network
#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.
30 Aug, 2022 | 12:12h | UTCNews Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In the #COVID-PACT 2×2 factorial RCT, full-dose prophylactic anticoagulation, but not the addition of clopidogrel, reduced thrombotic complications but w/ increased bleeding among critically-ill patients w/ COVID-19 https://t.co/UNxFCIC5B9 pic.twitter.com/p5LGmpCGeL
— Circulation (@CircAHA) August 29, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.
26 Aug, 2022 | 13:05h | UTCSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022